TMS (4891.T, JPX) drops 4.46% after earnings on 20 Jan 2026: what to watch
TMS Co., Ltd. (4891.T) moved lower in after-hours trading, closing at ¥150.00, down ¥7.00 (-4.46%) after its earnings event on 20 Jan 2026. The market reaction follows an update tied to clinical progress and results timing. Volume rose to 368,300.00 shares, above the average of 302,742.00, signalling active repositioning. We summarise the earnings takeaways, valuation, technicals and near-term catalysts for the JPX-listed biotech.
4891.T stock: Earnings snapshot and timing
TMS reported its earnings announcement on 20 Jan 2026. Investors focused on clinical trial milestones for TMS-007 and near-term cash runway. The company listed earnings details in the Investing.com calendar source.
The immediate reaction pushed the price to a session low of ¥149.00 and a high of ¥153.00 before after-hours weakness. Trading shows higher-than-normal activity with 368,300.00 volume.
4891.T stock: Financials and valuation
TMS shows a market capitalisation of ¥7,095,778,092.00 and EPS of -15.64. The trailing PE stands at -9.97, reflecting losses while R&D-heavy biotech development continues. Book value per share is ¥65.78, and cash per share is ¥67.81, supporting liquidity.
Current ratios appear conservative for a small biotech, with a high current ratio of 23.99 indicating a strong cash position versus liabilities. The company reported year high ¥314.00 and year low ¥120.00.
4891.T stock: Technical picture and trading signals
Momentum indicators show short-term strength. RSI reads 62.77, and MACD histogram is 2.03, indicating bullish bias despite today’s drop. Bollinger bandwidth places price inside the ¥122.53–¥143.27 band, with the latest close above the middle band.
Price averages sit at ¥137.36 (50-day) and ¥150.46 (200-day). Relative volume is 1.12, so moves today reflect genuine interest. Short-term support is near ¥149.00 and resistance near ¥153.00.
4891.T stock: Meyka AI grade and analyst context
Meyka AI rates 4891.T with a score out of 100: 62.14 (B, HOLD). This grade factors in S&P 500 comparison, sector performance, financial growth, key metrics, and analyst consensus.
Independent ratings show a company score of C on 19 Jan 2026 from a third-party screener, highlighting mixed signals between balance-sheet strength and weak profitability. We position the rating as a cautious hold for risk-tolerant biotech exposure.
4891.T stock: Risks, catalysts and sector context
Primary catalysts are clinical readouts for TMS-007 and regulatory updates. A successful Phase 3 signal would re-rate the stock. Conversely, trial delays or funding gaps would pressure the price.
TMS sits in the Healthcare/Biotechnology sector on JPX, where peers trade at higher PEs. Sector averages show steadier profitability, so TMS needs clinical proof points to justify premium valuation.
4891.T stock: Price targets and scenario planning
We outline three realistic price targets. Conservative downside target: ¥120.00, reflecting the year low and trial risk. Base case: ¥170.00, assuming steady trial progress and no dilution. Optimistic target: ¥250.00, tied to positive late-stage data or partner licensing.
Each target links to catalysts: conservative reflects clinical delays, base assumes on-schedule milestones, and optimistic requires outsized clinical success or strategic partnership. Use position sizing and stop-loss discipline.
Final Thoughts
Key takeaways for 4891.T stock after-hours on 20 Jan 2026: the share price closed at ¥150.00, down ¥7.00 (-4.46%), on higher volume of 368,300.00. Fundamentals show deep R&D spending with EPS -15.64 and a trailing PE of -9.97. Liquidity metrics are healthy with cash per share ¥67.81 and a current ratio near 23.99. Meyka AI’s model projects a short-term monthly target of ¥205.07, implying upside of 36.71% versus the current ¥150.00. Forecasts are model-based projections and not guarantees. Investors should weigh clinical timeline risk, potential dilution, and sector comparators on JPX in their decision-making. For more detail see the earnings calendar Investing.com earnings calendar and our company page TMS 4891.T on Meyka.
FAQs
What drove the after-hours move in 4891.T stock today?
The after-hours drop followed the company’s earnings announcement on 20 Jan 2026 and clinical updates. Volume of 368,300.00 shares rose above average, indicating active repositioning around trial news and guidance.
What is Meyka AI’s view on 4891.T stock valuation?
Meyka AI assigns a 62.14 score (B, HOLD) to 4891.T stock. The model highlights strong cash buffers but weak profitability, giving a cautious hold stance until clinical catalysts materialise.
What are realistic price targets for 4891.T stock?
Scenario targets: conservative ¥120.00, base ¥170.00, optimistic ¥250.00. Targets depend on clinical readouts, partner deals, and dilution risk for 4891.T stock.
How should investors monitor 4891.T stock moving forward?
Track clinical milestones for TMS-007, filings, news on partnerships, and trading volume. Monitor EPS -15.64, cash per share ¥67.81, and Meyka AI updates for model revisions to 4891.T stock.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
